Bronnen:
Saper J, Lipton R, Kudrow D, et al. Primary results of PROMISE-1 (Prevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-1) trial: a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of eptinezumab for prevention of frequent episodic migraines. S20.001.,Lipton R, Kudrow D, Kasse E, et al. Increased migraine-free intervals with eptinezumab were associated with improved health-related quality-of-life outcomes through week 12: Results from the phase 3 PROMISE-1 trial. AAN 2018, abstract S32.002.
Saper J, Lipton R, Kudrow D, et al. Primary results of PROMISE-1 (Prevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-1) trial: a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of eptinezumab for prevention of frequent episodic migraines. S20.001.,Lipton R, Kudrow D, Kasse E, et al. Increased migraine-free intervals with eptinezumab were associated with improved health-related quality-of-life outcomes through week 12: Results from the phase 3 PROMISE-1 trial. AAN 2018, abstract S32.002.